[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Approves Label Update for HYQVIA\u00ae Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indication of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ZENOAQ"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Zenyaku Kogyo"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac Co.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metoject\u00ae Subcutaneous Injection Syringe (Methotrexate) Launched in Japan for Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Eisai"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives FDA Approval to Expand the Use of HYQVIA\u00ae to Treat Primary Immunodeficiency in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf\u00ae in Taiwan and select South-East Asian markets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Approval of CUVITRU\u2122 Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Chugai Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel\u00ae (darvadstrocel) in Complex Crohn\u2019s Perianal Fistulas","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan\u00ae Approved for Suppression and Treatment of Antibody-mediated Rejection in Organ Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metoject\u00ae Subcutaneous Injection Pen (methotrexate) Pen-Type Autoinjector Approved in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Eisai"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Rituxan (rituximab) is an anti-CD20 monoclonal antibody, which is now approved for the treatment of suppression and treatment of antibody-mediated rejection in organ transplantation.
Alofisel (darvadstrocel) is a dispersion of expanded allogeneic (or donor-derived), adipose-derived mesenchymal stem cells (eASC) for the treatment of complex CPF in adult patients with non-active or mildly active luminal Crohn’s disease.
Cuvitru™ (Immune Globulin) is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated in Japan as a treatment for agammaglobulinemia or hypogammaglobulinemia in patients aged 2 years and older.
Actemra (tocilizumab) is designed to block the activity of IL-6, a type of inflammatory cytokine, which is indicated for the treatment of Cytokine Release Syndrome Induced by Cancer Therapy in Japan.
Under the agreement, Menarini will develop, manufacture and commercialise orally administered Janus kinase (JAK) inhibitor Smyraf Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis.
Hyqvia® is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins (Ig) and approved in the United States to treat adults and children two years of age and older with primary immunodeficiency (PI).
Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan. It is approved in approximately 50 countries, primarily in Europe.
Rituxan, an anti-CD20 monoclonal antibody got approval in additional indications of refractory pemphigus vulgaris and pemphigus foliaceus by MHLW based on results of investigator-initiated phase II clinical trial in Japan of KCTR-D006 study and PEMPHIX study.
Rituxan is an anti-CD20 monoclonal antibody that specifically binds to CD20. Clinical development of Rituxan for systemic sclerosis was conducted as an investigator-initiated phase II clinical trial (IDEC-C2B).